Clinical Efficacy and Safety of Pimobendan in Treatment of Heart Failure – Experience in Japan

Cardiology (Switzerland)

Volumn 88, Issue , 1997, Pages 28-36

  Kato, Kazuzo ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Anaerobic threshold; Exercise tolerance; Haemodynamic effects; NYHA functional class; Physical Activity Index; Specific Activity Scale

Indexed keywords

PIMOBENDAN;

ANAEROBIC THRESHOLD; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; HEADACHE; HEART FAILURE; HEART INDEX; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPOTENSION; JAPAN; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE;

ADMINISTRATION, ORAL; CARDIOTONIC AGENTS; DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; JAPAN; PYRIDAZINES;

EID: 0030895197     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177482     Document Type: Article

References (38)

1. Verdouvv PD. Hartog JM. Duncker DJ. Roth W, Saxena PR: Cardiovascular profile of pimobendan. a benzimidazolc-pyridazinone derivative with vasodilating and inotropic properties. EurJ Pharmacol 1986:126:21-30.
2. 2+ sensitivity of contractile proteins. Circulation 1986;73(suppl III):11178-11183.
3. Van Mcel JCA: Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo. Arzneimittel Forsch 1985:35: 284-288.
4. Berger C. Meyer W. Scholz H. Starbatty J: Effect of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl) benzimidazole HCI on phosphodiesterase activity and force of contraction in guinea-pig hearts. Arzneimittel Forsch (Drug Res) 1985:35:1668.
5. Van Meel JCA: Effects of some cardiotonic agents on contractility of skinned fibers from mammalian heart. Arzneimittel Forsch (Drug Res) 1987;37(suppl 1):679-682.
6. 2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988:63:911-922.
7. Havashi H. Nakashima M, Tanahashi T. Ito A. Tsunekawa A. Hiravama H, Inagaki H, Nomura II: Clinical evaluation of pimobendan (UD-CG 115 BS) on acute heart failure. Dose-finding study for a multicenter double-blind group comparison (in Japanese). Ther Res 1992:13: 591-612.
8. Havashi H. Nakashima M. Tanahashi T. Ta-katsu F. lto A. Hiravama H, Tsunekawa A. Inagaki H: Clinical evaluation of single oral administration of 2.5 mg pimobendan (UD-CG 115 BS) on acute heart failure. Multiccnter double-blind placebo-controlled comparative studv(in Japanese). Rinsho Ivaku 1992:8:813-832.
9. Renard M. Walter M. Liebens I. Dresse A. Bernard R: Pimobendan (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest 1988:93:1159-1164.
10. Hauf GF. Grom E. Jahnchcn E. Roskamm H: Acute and long-term hemodynamic cITccts of pimobendan (UD-CG 115 BS) in comparison with captopril. J Cardiovasc Pharmacol 1989: 14(suppl 2):S49-S56.
11. Abmann I. Kassel P. Duck HG, Fiehriug H. Morgan P. Schmidt PKH. Hofs T, Neltmiz G: Acute and long-term effects of pimobendan (UD-CG 115) in patients with heart failure (NYHA classes II and 111). Results of a randomized multiccnter double-blind study (in German). Zeilsehr Kardiol 1991:80:687-697.
12. Erlcmeier HH. Kupper W. Bleifeld W: Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril-a double-blind randomized study. Eur Heart J 1991:12:889-899.
13. Hagemeijer F: Intractable heart failure despite angiotensin-converting enzyme inhibitors, di-goxin. and diuretics: long-term effectiveness of add-on therapy with pimobendan. Am Heart J 1991:122:517-522.
14. Kato K. Yasuda K. Kawai C, Kumada T. Sugi-moto T. Kimata S. Taniguchi K. Sasayama S, Ota M. Kusukawa R, Nakajima M: Clinical efficacy of pimobendan for patients with chronic heart failure. A dose-finding study by a multiccnter double-blind comparison trial (in Japanese). Rinsho Iyaku 1991;7:2643-2669.
15. Remme WJ, Krayenbiihl HP. Baumann G, Frick MH, Haehl M. Nchniiz G. Baiker W: Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. Eur Heart J 1994:15:947-956.
16. Katz SD. Kubo SH. Jessup M. Brozcna S. Tro-ha JM. Wahl J. Cohn JN. Sonnenblick EH. LeJcmtcl TH: A multicenter, randomized, double-blind. placebo-controlled trial of pimobendan. a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992:123:95-103.
17. Van Meel JCA, Diederen W: Hemodynamic profile of ihc cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989:14(suppl 2): S1-S6.
18. Scheld HH. Fritschc R, Schlcppcr M. van Meel JCA: Pimobendan increases calcium sensitivity of skinned human papillary muscle fibers. J Clin Pharmacol 1989;29:360-365.
19. Solaro RJ. Fujino K. Sperclakis N: The positive inotropic effect of pimobendan involves sterco-specific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol 1989;14(suppl 2):S7-S12.
20. Rüegg JC, Morano I: Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 1989; 14(suppl 2):S20-S23.
21. Holubarsch Ch. Hascnfuss G. Just H. Blanchard E. Mulieri LA. Alpert NR: Influence of the positive inotropic substance pimobendan (UD-CG 115 BS) on contractile economy of guinea pig papillary muscles. J Cardiovasc Pharmacol 1989:14(suppl 2):S13-S17.
22. Lee JA, Allen DG: Calcium sensitizers. A new approach to increasing the strength of the heart. BMJ 1990:300:551-552.
23. Walter M, Liebcns I, Goethals H, Renard M, Dresse A, Bernard R: Pimobendan (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic crossover and double-blind study with two different doses. Br J Clin Pharmacol 1988:25:323-329.
24. Rent me WJ. Wiesfeld ACP. Look MP. Kruyss-en HACM: Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1989:14(suppl 2):S41-S44.
25. Hagemeijer F. Brand HJ, van Mechelen R: Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989:63:571-576.
26. Hagemeijer F. Brand HJ. Roth W: Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol 1989:14:302-310.
27. Tsuda T. Izunti T. Kodama M. Hanawa H. Takahashi M. Suzuki M. Aizaki T. Uchiyama IL Kuwano H, Shibata A: Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. Jpn Heart J 1992:33:193-203.
28. Taniguchi K, Hiroe M. Niwa A. Umczawa S. Izumi T. Miyahara Y. Nakamura S, lto H. Nakamura M. Tsujibayashi T: Hemodynamic and clinical effects of pimobendan (UD-CG 115 BS) capsules on acute heart failure by a single oral administration (in Japanese). Yakuri to Chiryo 1992;20:1347-1361.
29. Kubo SH. Gollub S. Bourgc R. Rahko P. Cobb F. Jessup M. Brozena S. Brodsky M. Kirlin P. Shanes J. Konstam M. Gradman A, Morledge J. Cinquegrani M. Singh S. LeJemtel T. Nicklas J. Troha J. Cohn JN: Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 1992:85:942-949.
30. Rector TS. Cohn JN: Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992:124:1017-1025.
31. Bergler-Klein J. Globits S. Stcfcnelli T. Mavr H. Porenta G. Sochor H, Glogar D: Pimobendan (UD CG 115 BS) in the long-term treatment of congestive heart failure (in German). Zeitschr Kardiol 1992;81:546-552.
32. Kato K. Yasuda H. lizuka M. Sukimoto T. Kimata S. Taniguchi K. Ota M. Kawai C. Sasayama S. Kusukawa R. Nakajima M: Evaluation of the efficacy and safety of pimobendan (UD-CG 115 BS) in treatment of chronic heart failure. A multicenter placebo-controlled double-blind study (in Japanese). Rinsho Ivaku 1992:8:1311-1351.
33. Hagemeijer F: Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement. and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993:14:551-566.
34. Sasayama S, Asanoi H. Kihara Y, Yokawa S. Terada Y. Yoshida S. Ejiri M, Horikoshi I: Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994:9:113-120.
35. Taniguchi K. Itoh H, Sakuma A. Niwa A. Nakamura S. Nakamura M. Miyahara Y. Izumi T: Acute effects of pimobendan on anaerobic threshold in patients with heart failure (in Japanese). Jpn J Clin Exp Med 1992:69:1634-1642.
36. Goldman L. Hashimoto B, Cook EF. Loscalzo A: Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981;64:1227-1234.
37. Sasayama S. Asanoi H. Ishizaka S: Evaluation of functional capacity of patients with congestive heart failure: in Yasuda H (ed): New Aspects in the Treatment of the Failing Heart. Berlin. Springer 1992, pp 113-117.
38. Tonkin AL. Houghes HM. Birkett DJ. Wing LMH. Roth W. Heinzel G: Pharmacokinetics of a new inotropic agent, pimobendan. in young and elderly subjects (abstract). Clin Exp Pharmacol Physiol 1990:17(suppl 16):31.